Barricaid is a proven technology that reduces reoperations for reherniations by 81% in a well-defined patient population. Learn about the clinical efficacy and superiority RCT for Barricaid from Oscar Yeh, Chief Operating Officer of Intrinsic Therapeutics, Inc in this payor-focused webinar, recorded on 12/9/21.
For full benefit/risk information, please visit www.barricaid.com/instructions. PPT22 Rev. A